June 16, 2014
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have hit the Japanese market for oral diabetes treatments, with four active pharmaceutical ingredients (APIs) now being promoted by eight companies. The first to debut was Suglat (ipragliflozin; Astellas Pharma/MSD), followed around a month later by...read more